Rybelsus Dosage Guide
Rybelsus is an oral semaglutide tablet for type 2 diabetes. It is the first oral GLP-1 receptor agonist. Taken once daily on an empty stomach[FDA PI].
Rybelsus Titration Schedule
| Days | Dose | Phase |
|---|---|---|
| 1 – 30 | 3 mg daily | Starter (not therapeutic) |
| 31 – 60 | 7 mg daily | Maintenance (option A) |
| 61+ (if needed) | 14 mg daily | Maintenance (option B) |
Source: Rybelsus FDA prescribing information (Novo Nordisk). 14 mg/day is the maximum approved dose.
How to take Rybelsus correctly
Rybelsus absorption is extremely sensitive to administration conditions. Taking it incorrectly cuts bioavailability dramatically.
- Morning, empty stomach. At least 30 minutes before any food, beverage, or other oral medication.
- Water only — maximum 4 oz (120 mL). More water, or any other liquid, reduces absorption.
- Swallow whole. Do not split, crush, or chew. Doing so destroys the formulation's absorption enhancer (SNAC).
- Wait 30 minutes before anything else goes in your mouth.
Why oral semaglutide requires so much more drug
Injected semaglutide (Wegovy, Ozempic) achieves therapeutic plasma levels at 1–2 mg per week. Oral semaglutide (Rybelsus) requires 7–14 mg per day to reach comparable exposure — roughly 50× more drug. This is because peptides are poorly absorbed through the gut unless formulated with an absorption enhancer. Rybelsus uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate), which transiently permeabilizes the gastric epithelium and locally raises pH to protect the peptide. Even with SNAC, bioavailability is only about 1%, which is why dosing conditions are so strict[FDA PI §12.3].
Dosage adjustments
Renal impairment: no dose adjustment required for mild–severe renal impairment. Limited data in ESRD. Hepatic impairment: no adjustment. Pediatric: not approved under age 18. Geriatric: no adjustment, but monitor for dehydration from GI effects.
Side effects
Nausea is the most common side effect, affecting roughly 15% of patients at 7 mg and 20% at 14 mg. Diarrhea, constipation, and decreased appetite are also common. Effects are dose-related and generally improve after 4–8 weeks at a given dose[FDA PI §6.1].
Boxed warning: Risk of thyroid C-cell tumors based on rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome[FDA PI].
References
- Rybelsus (oral semaglutide) FDA prescribing information. Current label PDF · Drugs@FDA overview (NDA 213051)
- Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 5 — Oral semaglutide in patients with T2DM and moderate renal impairment. Lancet Diabetes Endocrinol 2019. PubMed 31189517
- All PIONEER trials (oral semaglutide program). PubMed search
- Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of semaglutide enabled by SNAC. Sci Transl Med 2018. PubMed search